Gary A Lyons
Director at Neurocrine Biosciences Inc (NBIX); Director at Travere Therapeutics, Inc. (TVTX)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $3.3M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Aug 19SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 1,90064,600 held (−3%) | $62.53 | $119K | -16.6% |
| Aug 19SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 2,60062,000 held (−4%) | $63.50 | $165K | -17.9% |
| Aug 19SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 50061,500 held (−1%) | $64.16 | $32K | -18.8% |
| Aug 19SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 4,10062,400 held (−6%) | $63.27 | $259K | -17.6% |
| Aug 19SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 90061,500 held (−1%) | $63.86 | $57K | -18.4% |
| Apr 16SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 8,00057,500 held (−12%) | $41.07 | $329K | +26.9% |
| Dec 4SEC | NBIXNeurocrine Biosciences Inc | Sell Plan | 15,000120,482 held (−11%) | $152.61 | $2.3M | -6.7% |
- Sell
Director Gary A Lyons sold $119K of TVTX at $62.53 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Gary A Lyons sold $165K of TVTX at $63.50 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Gary A Lyons sold $32K of TVTX at $64.16 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Gary A Lyons sold $259K of TVTX at $63.27 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Gary A Lyons sold $57K of TVTX at $63.86 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Gary A Lyons sold $329K of TVTX at $41.07 — pre-scheduled 10b5-1 plan sale.